Skip to main content
SpringerLink
Log in

Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia

  • Leading Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

A Correction to this article was published on 21 July 2023

This article has been updated

Abstract

Patients with arrythmias are at an increased risk of heart-related comorbidities and complications. Specifically, patients with paroxysmal supraventricular tachycardia (PSVT), a type of arrythmia, are at increased risk of lightheadedness or shortness of breath, due to the increased rate of the heartbeat. Most patients are prescribed oral medications to control their heart rates and maintain a normal heart rhythm. Researchers have been tasked with discovering alternative treatment options with new delivery methods to treat arrythmias such as PSVT. A nasal spray was subsequently designed and is currently undergoing clinical studies. This review aims to present and discuss the current clinical and scientific evidence pertaining to etripamil.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

References

  1. Sohinki D, Obel OA. Current trends in supraventricular tachycardia management. Ochsner J. 2014;14(4):586–95.

    PubMed  PubMed Central  Google Scholar 

  2. Rehorn M, Sacks NC, Emden MR, et al. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol. 2021;32:2199–206. https://doi.org/10.1111/jce.15109.

    Article  PubMed  Google Scholar 

  3. Anon. Paroxysmal supraventricular tachycardia (PSVT). Johns Hopkins Medicine. 2020. https://www.hopkinsmedicine.org/health/conditions-and-diseases/paroxysmal-supraventricular-tachycardia. Accessed 8 May 2023.

  4. Hafeez Y, Quintanilla Rodriguez BS, Ahmed I, et al. Paroxysmal Supraventricular Tachycardia. [Updated 2023 Feb 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK507699/.

  5. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011;13(9):687–9. https://doi.org/10.1111/j.1751-7176.2011.00513.x.

    Article  CAS  PubMed  Google Scholar 

  6. Anon. Supraventricular tachycardia. Mayo Clinic. 2022. https://www.mayoclinic.org/diseases-conditions/supraventricular-tachycardia/symptoms-causes/syc-20355243. Accessed 7 Jan 2023.

  7. Milestone Pharmaceuticals Inc. Registration statement filed with the United States Securities and Exchange Commission on April 12, 2019. https://www.sec.gov/Archives/edgar/data/1408443/000104746919002213/a2238338zs-1.htm. Accessed 8 May 2023.

  8. Stambler BS, Dorian P, Sager PT, et al. Etripamil nasal spray for rapid conversion of supraventricular tachycardia to sinus rhythm. J Am Coll Cardiol. 2018;72(5):489–97. https://doi.org/10.1016/j.jacc.2018.04.082.

    Article  CAS  PubMed  Google Scholar 

  9. Chu GS, Gupta D. Update on etripamil nasal spray for the at-home treatment of acute paroxysmal supraventricular tachycardia. Heart Int. 2021;15(1):2–6. https://doi.org/10.17925/HI.2021.15.1.2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Milestone Pharma. Press release dated March 30, 2021. https://milestonepharma.com/research-development/etripamil. Accessed 8 May 2023.

  11. Choe WC, Sundaram S, Boorman C, et al. High-density mapping of the slow pathway in a patient with atrioventricular nodal reentry given intranasal etripamil during the NODE-1 study. HeartRhythm Case Rep. 2017;3(10):479–82. https://doi.org/10.1016/j.hrcr.2017.07.011.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Stambler BS, Plat F, Sager PT, et al. First randomized, multicenter, placebo-controlled study of self-administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301). Circ Arrhythm Electrophysiol. 2022;15(12):e010915. https://doi.org/10.1161/CIRCEP.122.010915.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Efficacy and safety study of etripamil nasal spray self-administration for the termination of spontaneous episodes of paroxysmal supraventricular tachycardia. https://clinicaltrials.gov/ct2/show/NCT05410860. Accessed 8 May 2023.

  14. Neale T. Rapid: positive top-line results for etripamil nasal spray in paroxysmal SVT. TCTMD.com. 2022. https://www.tctmd.com/news/rapid-positive-top-line-results-etripamil-nasal-spray-paroxysmal-svt. Accessed 8 May 2023.

  15. Etripamil nasal spray in patients with paroxysmal supraventricular tachycardia. https://clinicaltrials.gov/ct2/show/NCT04952610. Accessed 8 May 2023.

  16. Kashou AH, Noseworthy PA. Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT). Expert Opin Investig Drugs. 2020;29(1):1–4. https://doi.org/10.1080/13543784.2020.1703180. (Epub 2019 Dec 12).

    Article  CAS  PubMed  Google Scholar 

  17. Safety study ofetripamil nasal spray for patients with paroxysmal supraventricular tachycardia. NODE-303. https://clinicaltrials.gov/ct2/show/NCT04072835. Accessed 8 May 2023.

  18. Safety study of intranasaletripamil for the termination of spontaneous episodes of paroxysmal supraventricular tachycardia (PSVT). NODE-302. https://clinicaltrials.gov/ct2/show/NCT03635996. Accessed 8 May 2023.

  19. The NODE-202 Study (study ofetripamil nasal spray in pediatric patients). https://clinicaltrials.gov/ct2/show/NCT05763953. Accessed 8 May 2023.

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, University of Florida, Jacksonville, FL, USA

    Jessica Huston

  2. East Coast Institute for Research, Jacksonville, FL, USA

    Ariana Genovese, Andrea Ashchi, Amanda DeLuca, Jordyn Wiener, Elias Deeb, Alexander Deeb & Rebecca F. Goldfaden

Authors
  1. Jessica Huston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ariana Genovese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Ashchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amanda DeLuca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jordyn Wiener
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elias Deeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexander Deeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rebecca F. Goldfaden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rebecca F. Goldfaden.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

Jessica Huston, Ariana Genovese, Andrea Ashchi, Amanda DeLuca, Jordyn Wiener, Elias Deeb, Alexander Deeb, and Rebecca F. Goldfaden declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Data availability statement

Data sharing not applicable to this article as no datasets were generated.

Code availability

Not applicable.

Authors’ contributions

Jessica Huston was involved in supervision, data curation, analysis, reviewing, editing, and writing. Ariana Genovese was involved in data curation, analysis, and writing. Andrea Ashchi was involved in data curation, writing, and analysis. Amanda DeLuca was involved in data curation, analysis, and writing. Jordyn Wiener was involved in data curation, analysis, and writing. Elias Deeb was involved in data curation, analysis, and writing. Alexander Deeb was involved in data curation, analysis, and writing. Rebecca Goldfaden was involved in the conceptualization, project administration, reviewing, and editing.

Additional information

The original online version of this article was revised to correct few statements in the text.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huston, J., Genovese, A., Ashchi, A. et al. Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia. Am J Cardiovasc Drugs 23, 471–475 (2023). https://doi.org/10.1007/s40256-023-00589-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-023-00589-2

Search

Navigation